China-based Luye Pharma Group (HKG: 2186) has announced that the market approval filing for its biosimilar version of Roche’s Avastin (bevacizumab) has been accepted for review by Brazil’s National Health Surveillance Agency (ANVISA).
Luye’s Biosimilar Approval and Global Outlook
Luye’s biosimilar bevacizumab was approved in China in 2021 to treat indications such as non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC). The company is actively pursuing overseas commercialization for the drug, with the ANVISA review being a significant step in this direction.
Competition in the Bevacizumab Biosimilar Market
In addition to Luye Pharma, several other Chinese pharmaceutical companies have their bevacizumab biosimilars available in the Chinese market. These include Qilu Pharma, Innovent Bio, Henlius Pharma, Hengrui Medicine, Bio-Thera Solutions, Betta Pharma, Tot Bio, and Sino Bio. The presence of multiple biosimilar options reflects the competitive landscape in the biologics market, particularly for high-demand drugs like bevacizumab.-Fineline Info & Tech
